Hip fractures in users of first- vs. second-generation bisphosphonates

Osteoporosis International

Volumn 18, Issue 12, 2007, Pages 1595-1600

  Mamdani, M ^a,b,c,d   Kopp, A ^b   Hawker, G ^b,c,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Bisphosphonates; Hip fractures; Observational cohort study; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; RISEDRONIC ACID;

AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; CANADA; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SOCIAL STATUS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HIP FRACTURES; HOSPITALIZATION; HUMANS; ONTARIO; OSTEOPOROSIS, POSTMENOPAUSAL; RETROSPECTIVE STUDIES; SOCIAL CLASS;

EID: 35448956554     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0446-5     Document Type: Article

References (22)

1. Riggs BL, Melton LJ 3rd (1995) The worldwide problem of osteoporosis insights afforded by epidemiology. Bone 17(Suppl):505S-511S
2. Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739
3. Wu F, Mason B, Horne A et al (2002) Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures. Arch Intern Med 162:33-36
4. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
5. Kado DM, Browner WS, Palermo L et al (1999) Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159:1215-1220
6. North American Menopause Society (2002) Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause 9:84-101
7. Goeree R, O'Brien B, Pettitt D et al (1996) An assessment of the burden of illness due to osteoporosis in Canada. J Soc Obstet Gynaecol Can 18(Suppl):15-24
8. Kanis KA (1993) Osteoporosis and its consequences. Osteoporosis. Blackwell Science Ltd, Oxford, p 18
9. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
10. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
11. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340
12. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
13. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
14. Storm T, Thamsborg G, Steiniche T et al (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271
15. Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9:461-468
16. Ontario Ministry of Health and Long-Term Care (2005) Ontario Drug Benefit Formulary/Comparative Drug Index No. 39. http://www.health.gov.on.ca/english/ providers/program/drugs/formulary/ed39_0_bk.pdf
17. Levy AR, O'Brien BJ, Sellors C et al (2003) Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10:67-71
18. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154:854-864
19. Bashford JN, Norwood J, Chapman SR (1998) Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 317:452-456
20. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856-861
21. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
22. Van den Boogaard CHA, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Goettsch WG, Herings RM (2006) Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 22:1757-1764